<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="with cascade principle for treatment of animal diseases (e.g. acyclovir," exact="idoxuridine" post="and trifluridine against feline herpesvirus-1 ocular infection in cats)"/>
 <result pre="contribute to identification of new lead bioactive species (Prichard 2007)." exact="Vidarabine" post="Vidarabine (9-d-arabinofuranosyl adenine) was the first antiviral agent licensed"/>
 <result pre="to identification of new lead bioactive species (Prichard 2007). Vidarabine" exact="Vidarabine" post="(9-d-arabinofuranosyl adenine) was the first antiviral agent licensed for"/>
 <result pre="infections in humans (Fenner et al. 2014). It is an" exact="adenosine" post="analogue that is converted by cellular enzymes to its"/>
 <result pre="is converted by cellular enzymes to its active intracellular derivate," exact="vidarabine" post="triphosphate. Obtained triphosphate form further acts as competitive inhibitor"/>
 <result pre="to be less potent against feline herpesviruses than trifluridine and" exact="idoxuridine" post="(Nasisse 1990). In vitro activity has also been demonstrated"/>
 <result pre="2004; Gaskell et al. 2007; Nasisse et al. 1989). The" exact="acyclovir" post="prodrug valacyclovir shows better pharmacokinetic properties in terms of"/>
 <result pre="et al. 2007; Nasisse et al. 1989). The acyclovir prodrug" exact="valacyclovir" post="shows better pharmacokinetic properties in terms of its enhanced"/>
 <result pre="upon which it gets rapidly metabolized to acyclovir. Acyclovir and" exact="entecavir" post="had the ability to block nucleic acid synthesis (Fig."/>
 <result pre="to block nucleic acid synthesis (Fig. 22.1). However, administration of" exact="valacyclovir" post="as well as subsequent increased plasma acyclovir concentrations has"/>
 <result pre="However, administration of valacyclovir as well as subsequent increased plasma" exact="acyclovir" post="concentrations has been associated with adverse effects, such as"/>
 <result pre="et al. 1989). These findings suggest systemic administration of neither" exact="acyclovir" post="nor valacyclovir is recommended for treatment of herpesvirus infections"/>
 <result pre="1989). These findings suggest systemic administration of neither acyclovir nor" exact="valacyclovir" post="is recommended for treatment of herpesvirus infections in cats."/>
 <result pre="infections in cats. Ganciclovir, another purine nucleoside analogue that resembles" exact="acyclovir" post="and is widely used to treat cytomegalovirus infections in"/>
 <result pre="safety in animals (Sykes 2013). On the other hand, topical" exact="acyclovir" post="treatment was shown to be effective against FHV-1 conjunctivitis"/>
 <result pre="2005). Apart from cats, the existing studies provide data on" exact="acyclovir" post="treatment in horses, where intravenous administration resulted in 9,6-hour"/>
 <result pre="Papich 2013). In birds, oral treatment with 120 mg/kg of" exact="acyclovir" post="every 12 h has been shown as the minimum"/>
 <result pre="et al. 2001). Studies in dogs report oral absorption of" exact="acyclovir" post="of 80–90%, but it becomes saturated at high doses"/>
 <result pre="becomes saturated at high doses (de Miranda et al. 1981)." exact="Penciclovir" post="Penciclovir [9-(4-hydroxy-3-hydroxymethylbut-1-yl)] is guanosine analogue that resembles acyclovir in"/>
 <result pre="saturated at high doses (de Miranda et al. 1981). Penciclovir" exact="Penciclovir" post="[9-(4-hydroxy-3-hydroxymethylbut-1-yl)] is guanosine analogue that resembles acyclovir in structure,"/>
 <result pre="al. 1981). Penciclovir Penciclovir [9-(4-hydroxy-3-hydroxymethylbut-1-yl)] is guanosine analogue that resembles" exact="acyclovir" post="in structure, mechanism of action and antiviral activity spectrum."/>
 <result pre="Gill and Wood 1996). However, it is less potent than" exact="acyclovir" post="triphosphate as it exhibits lower affinity for viral DNA"/>
 <result pre="and Boyd 1996). Because of penciclovir’s poor oral bioavailability (&amp;lt;5%)," exact="famciclovir" post="was developed as the oral formulation (Salvaggio and Gnann"/>
 <result pre="the oral formulation (Salvaggio and Gnann 2017). The use of" exact="penciclovir" post="will be further described along with famciclovir. Famciclovir Famciclovir"/>
 <result pre="use of penciclovir will be further described along with famciclovir." exact="Famciclovir" post="Famciclovir (the diacetyl ester of 6-deoxy-penciclovir) is the oral"/>
 <result pre="of penciclovir will be further described along with famciclovir. Famciclovir" exact="Famciclovir" post="(the diacetyl ester of 6-deoxy-penciclovir) is the oral prodrug"/>
 <result pre="(the diacetyl ester of 6-deoxy-penciclovir) is the oral prodrug of" exact="acyclovir" post="with the improved bioavailability which, following oral administration, gets"/>
 <result pre="following oral administration, gets rapidly converted to its active metabolite" exact="penciclovir" post="by di-deacetylation and oxidation. However, the pharmacokinetics of penciclovir"/>
 <result pre="metabolite penciclovir by di-deacetylation and oxidation. However, the pharmacokinetics of" exact="penciclovir" post="and famciclovir in cats appears to be nonlinear (saturable)"/>
 <result pre="by di-deacetylation and oxidation. However, the pharmacokinetics of penciclovir and" exact="famciclovir" post="in cats appears to be nonlinear (saturable) and absorption"/>
 <result pre="by the observation that administration of the same doses of" exact="famciclovir" post="to cats and other species resulted in much lower"/>
 <result pre="plasma concentrations in cats (Thomasy et al. 2007). Thus, limited" exact="famciclovir" post="metabolism stems from deficiency of hepatic aldehyde oxidase enzyme"/>
 <result pre="deficiency of hepatic aldehyde oxidase enzyme in cats, which converts" exact="famciclovir" post="to its active form (Dick et al. 2005). Even"/>
 <result pre="to its active form (Dick et al. 2005). Even though" exact="famciclovir" post="has to be administered in high oral doses to"/>
 <result pre="mg famciclovir/kg to cats resulted in equivalent serum and tear" exact="penciclovir" post="concentrations, implying that 40 mg/kg is equally effective against"/>
 <result pre="higher dose (Thomasy et al. 2012). In rats and dogs," exact="famciclovir" post="absorption and metabolism appear to be similar to those"/>
 <result pre="previously reported in people, despite the observed slower conversion of" exact="famciclovir" post="to penciclovir in both species (Filer et al. 1994)."/>
 <result pre="in people, despite the observed slower conversion of famciclovir to" exact="penciclovir" post="in both species (Filer et al. 1994). Ribavirin As"/>
 <result pre="famciclovir to penciclovir in both species (Filer et al. 1994)." exact="Ribavirin" post="As first described by Witkowski et al. in 1972,"/>
 <result pre="Ribavirin As first described by Witkowski et al. in 1972," exact="ribavirin" post="(1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a triazole nucleoside analogue that inhibits replication"/>
 <result pre="2007). It has several possible mechanisms of action. Firstly, as" exact="ribavirin" post="monophosphate, generated by adenosine kinase-mediated phosphorylation, it can indirectly"/>
 <result pre="possible mechanisms of action. Firstly, as ribavirin monophosphate, generated by" exact="adenosine" post="kinase-mediated phosphorylation, it can indirectly inhibit the synthesis of"/>
 <result pre="GTP to RNA polymerase (Riviere and Papich 2013). Orally administered" exact="ribavirin" post="has been shown to worsen the condition of cats"/>
 <result pre="and include depression of red and white blood cells, increased" exact="alanine" post="aminotransferase activity, icterus and body weight loss. However, observed"/>
 <result pre="infectious peritonitis virus (FIPV), treatment with neither free nor liposomal" exact="ribavirin" post="improved survival rate and, similarly to animals infected with"/>
 <result pre="(Riviere and Papich 2013; Weiss et al. 1993). Activity of" exact="ribavirin" post="has also been demonstrated against bovine viral diarrhoea virus,"/>
 <result pre="biological activities. Biologically active compounds such as vitamin B12, albendazole," exact="mebendazole" post="and thiabendazole contain a benzimidazole nucleus in their structure"/>
 <result pre="Biologically active compounds such as vitamin B12, albendazole, mebendazole and" exact="thiabendazole" post="contain a benzimidazole nucleus in their structure (Fig. 22.2)"/>
 <result pre="of benzimidazole derivatives are available in the market such as" exact="omeprazole" post="and rabeprazole used for gastric ulcers, telmisartan and candesartan"/>
 <result pre="derivatives are available in the market such as omeprazole and" exact="rabeprazole" post="used for gastric ulcers, telmisartan and candesartan for hypertension,"/>
 <result pre="market such as omeprazole and rabeprazole used for gastric ulcers," exact="telmisartan" post="and candesartan for hypertension, astemizole and mizolastine for allergic"/>
 <result pre="rabeprazole used for gastric ulcers, telmisartan and candesartan for hypertension," exact="astemizole" post="and mizolastine for allergic rhinitis, and albendazole, oxibendazole and"/>
 <result pre="astemizole and mizolastine for allergic rhinitis, and albendazole, oxibendazole and" exact="mebendazole" post="for parasitosis (Wang et al. 2015). Benzimidazoles readily interact"/>
 <result pre="than the polymerase. Arildone is administered as a solution in" exact="dimethyl sulphoxide" post="(DMSO) due to its poor solubility in water, and"/>
 <result pre="rifamycins isolated from bacteria, the most widely used derivative of" exact="rifampicin" post="(rifampin) is a semisynthetic rifamycin. Rifamycins are preferable as"/>
 <result pre="some act by inhibiting the bacterial DNA-dependent RNA polymerase. Furthermore," exact="rifampin" post="inhibits poxvirus replication in vitro via a mechanism other"/>
 <result pre="type II topoisomerase (Zakaryan and Revilla 2016). Rifampicin, rifapentine and" exact="rifabutin" post="(Fig. 22.5) are semisynthetic and water-soluble derivatives of 3-formylrifamycin"/>
 <result pre="against a number of ailments. It is a synthetic second-generation" exact="tetracycline" post="derivative with immunomodulatory and anti-inflammatory action and widely used"/>
 <result pre="to their antibacterial and anticancer activity. Particularly the antimalarial drugs" exact="chloroquine" post="and amodiaquine displayed activity against viruses like dengue virus,"/>
 <result pre="have been isolated from marine cyanobacteria. Marketed marine products include" exact="cytarabine" post="(Cytosar) for non-Hodgkin’s lymphoma, the antiviral vidarabine (Vira-A), ziconotide"/>
 <result pre="marine products include cytarabine (Cytosar) for non-Hodgkin’s lymphoma, the antiviral" exact="vidarabine" post="(Vira-A), ziconotide (Prialt) and trabectedin (Yondelis) (Demain 2014). Herbal"/>
 <result pre="for non-Hodgkin’s lymphoma, the antiviral vidarabine (Vira-A), ziconotide (Prialt) and" exact="trabectedin" post="(Yondelis) (Demain 2014). Herbal Antiviral The history of herbal"/>
 <result pre="over 20 years in Japan for treatment of hepatitis. Its" exact="dried" post="and processed root licorice has a unique odour and"/>
 <result pre="with Ebola virus-like particle entry-blocking activity including the macrolide antibiotics" exact="azithromycin" post="and clarithromycin, which block bacterial protein synthesis (Kouznetsova et"/>
 <result pre="methyltransferase inhibitor and repurposed drugs. Repurposed drugs such as chloroquine," exact="azithromycin" post="and niclosamide are used for the treatment of Zika"/>
 <result pre="and repurposed drugs. Repurposed drugs such as chloroquine, azithromycin and" exact="niclosamide" post="are used for the treatment of Zika virus infection"/>
 <result pre="with Zika virus infection. Therefore, blocking of NMDAR channels with" exact="memantine" post="and/or other antagonists helps to lessen the neuronal damage"/>
 <result pre="that possess antiviral properties, such as indoleamine 2,3-dioxygenase and inducible" exact="nitric oxide" post="synthase (Moraes et al. 2007). One of the most"/>
 <result pre="nucleotide analogues have been reported for topical administration, such as" exact="vidarabine" post="that affects DNA polymerase and subsequently disrupts DNA synthesis,"/>
 <result pre="which acts as a fluorinated nucleoside analogue of thymidine and" exact="cidofovir" post="which is a cytosine analogue acting on two host-mediated"/>
 <result pre="of respiratory and various neurological diseases in horses, against which" exact="acyclovir" post="and valacyclovir are the most common drugs, but also"/>
 <result pre="and various neurological diseases in horses, against which acyclovir and" exact="valacyclovir" post="are the most common drugs, but also IFN targeting"/>
 <result pre="the enzyme (Hartmann et al. 2015). The first among them," exact="zidovudine" post="(AZT), has been reported to improve the immunologic and"/>
 <result pre="marrow suppression (Hartmann 1998). Another drug acting as RTI is" exact="stavudine" post="that has been shown to be active against FIV"/>
 <result pre="FIV in vitro, however with many resistant strains arisen. Similarly," exact="didanosine" post="and lamivudine have shown potency against FIV in in"/>
 <result pre="vitro, however with many resistant strains arisen. Similarly, didanosine and" exact="lamivudine" post="have shown potency against FIV in in vitro conditions"/>
 <result pre="vitro conditions (Schwartz et al. 2014). Additionally, a combination of" exact="zidovudine" post="and lamivudine has been investigated, resulting in synergistic anti-FIV"/>
 <result pre="(Schwartz et al. 2014). Additionally, a combination of zidovudine and" exact="lamivudine" post="has been investigated, resulting in synergistic anti-FIV effects in"/>
 <result pre="and survival of infected cats (de Mari et al. 2004)." exact="Idoxuridine" post="and trifluridine are structurally similar thymidine analogues that inhibit"/>
 <result pre="number of viral plaques in vitro (Nasisse et al. 1989)." exact="Idoxuridine" post="has also exhibited therapeutic potential against equine herpesvirus type"/>
 <result pre="(Collinson et al. 1994). It has also been reported that" exact="idoxuridine" post="in the concentration of 0.1% and 0.3% trifluridine can"/>
 <result pre="immunopathogenesis?Vet Immunol Immunopathol2002853–418920410.1016/S0165-2427(01)00426-311943320 AyisiNet al.Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with" exact="adenine" post="arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex"/>
 <result pre="Chem Biol201115453453910.1016/j.cbpa.2011.05.02321684803 Bryan-MarrugoOet al.History and progress of antiviral drugs: from" exact="acyclovir" post="to direct-acting antiviral agents (DAAs) for Hepatitis CMed Univ20151768165174"/>
 <result pre="clinical trialsNat Prod Rep200825347551610.1039/b514294f18497896 CanonicoPGEfficacy, toxicology and clinical applications of" exact="ribavirin" post="against virulent RNA viral infectionsAntivir Res19855758110.1016/S0166-3542(85)80011-53160302 ChenJJet al.Synthesis and"/>
 <result pre="symptomatic catsJ Vet Intern Med200418447748210.1111/j.1939-1676.2004.tb02570.x15320583 de MirandaPet al.The disposition of" exact="acyclovir" post="in different speciesJ Pharmacol Exp Ther198121923093157288622 DebRet al.Monoclonal antibody"/>
 <result pre="MaggsDJClarkeHEIn vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and" exact="acyclovir" post="against feline herpesvirus type-1Am J Vet Res200465439940310.2460/ajvr.2004.65.39915077679 MalikRet al.Treatment"/>
 <result pre="MalikRet al.Treatment of feline herpesvirus-1 associated disease in cats with" exact="famciclovir" post="and related drugsJ Feline Med Surg2009111404810.1016/j.jfms.2008.11.01219154974 MaoJ-HRobishawEEOverbyLInhibition of DNA"/>
 <result pre="2, 5, 6-trichloro-1-(β-D-ribofuranosyl) benzimidazoleJ Med Chem19984181252126210.1021/jm970559i9548815 PoveyREffect of orally administered" exact="ribavirin" post="on experimental feline calicivirus infection in catsAm J Vet"/>
 <result pre="diseasesAntivir Chem Chemother19923631132610.1177/095632029200300601 Rush E et al (2001) Pharmacokinetics of" exact="acyclovir" post="in tragopans (tragopan sp.). in joint conference-american association of"/>
 <result pre="and emerging strategiesNat Rev Drug Discov2002186710.1038/nrd93712415247 TeHSRandallGJensenDMMechanism of action of" exact="ribavirin" post="in the treatment of chronic hepatitis CGastroenterol Hepatol200733218 ThiryEet"/>
 <result pre="feline herpesvirus type 1Vet Ophthalmol20161911913010.1111/vop.1237527091747 ThomasySMet al.Pharmacokinetics and safety of" exact="penciclovir" post="following oral administration of famciclovir to catsAm J Vet"/>
 <result pre="ThomasySMet al.Pharmacokinetics and safety of penciclovir following oral administration of" exact="famciclovir" post="to catsAm J Vet Res200768111252125810.2460/ajvr.68.11.125217975982 ThomasySMet al.Pharmacokinetics of famciclovir"/>
 <result pre="of famciclovir to catsAm J Vet Res200768111252125810.2460/ajvr.68.11.125217975982 ThomasySMet al.Pharmacokinetics of" exact="famciclovir" post="and penciclovir in tears following oral administration of famciclovir"/>
 <result pre="to catsAm J Vet Res200768111252125810.2460/ajvr.68.11.125217975982 ThomasySMet al.Pharmacokinetics of famciclovir and" exact="penciclovir" post="in tears following oral administration of famciclovir to cats:"/>
 <result pre="of famciclovir and penciclovir in tears following oral administration of" exact="famciclovir" post="to cats: a pilot studyVet Ophthalmol201215529930610.1111/j.1463-5224.2011.00984.x22339892 TomeiLet al.Mechanism of"/>
 <result pre="review (2013–2014)Expert Opin Ther Pat201525559561210.1517/13543776.2015.101598725887338 WeissRCoxNMartinezMEvaluation of free or liposome-encapsulated" exact="ribavirin" post="for antiviral therapy of experimentally induced feline infectious peritonitisRes"/>
</results>
